Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Treasury Shares (2019 - 2025)

Burning Rock Biotech has reported Treasury Shares over the past 5 years, most recently at $8.1 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 8.44% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, down 8.44%, while the annual FY2025 figure was $8.2 million, 5.64% down from the prior year.
  • Treasury Shares for Q4 2025 was $426240.1 at Burning Rock Biotech, up from $420868.3 in the prior quarter.
  • Over five years, Treasury Shares peaked at $467847.9 in Q2 2021 and troughed at -$448108.7 in Q4 2022.
  • A 5-year average of $179040.5 and a median of $420868.3 in 2024 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: crashed 1569.07% in 2023 and later rose 14.44% in 2025.
  • Year by year, Treasury Shares stood at -$661000.0 in 2021, then surged by 1353.29% to $8.3 million in 2022, then grew by 10.48% to $9.2 million in 2023, then decreased by 3.77% to $8.8 million in 2024, then fell by 8.44% to $8.1 million in 2025.
  • Business Quant data shows Treasury Shares for BNR at $8.1 million in Q4 2025, -$8.0 million in Q3 2025, and -$8.5 million in Q2 2025.